Navigation Links
Graffinity Enters into Drug Discovery Research Collaboration with Genentech
Date:10/15/2009

Heidelberg, Germany, October 15, 2009 / b3c newswire / - Graffinity Pharmaceuticals GmbH announced today that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). With this collaboration Genentech will gain access to Graffinitys proprietary, fragment-based drug discovery technology.

Under the terms of the agreement, Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets. Financial details of the transaction were not disclosed.

Mathias Woker, Chief Business Officer of Graffinity, stated, We are very pleased that Genentech has decided to partner with us in fragment-based drug discovery. This marks our second collaboration with Genentech, and we think that this new agreement demonstrates how attractive Graffinitys very large fragment library and rapid surface plasmon resonance (SPR) screening technology are.

Kristina Schmidt, CEO of Graffinity, remarked, Our label-free, biophysics-based screening technology has shown to be an important element for companies which choose to work with us. With the help of this technology we enable partners, such as Genentech, to explore drug targets that would remain white spaces on the map of drug discovery, if researchers were limited to other conventional high-throughput screening techniques.


About Graffinity Pharmaceuticals GmbH - www.graffinity.com

Heidelberg, Germany based Graffinity Pharmaceuticals is a leader in the field of small molecule fragment based drug discovery. The company pursues high-profile drug discovery collaborations with leading pharmaceutical and biotechnology companies worldwide. Graffinity employs a flexible business model which allows it to tailor programs to the specific needs of each partner and offers numerous benefits to its customers on a straightforward fee-for-service basis. Graffinitys fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR imaging. The companys rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 23,000 true fragments, Graffinity possesses one of the most diverse fragment libraries. During the past three years Graffinity has established collaborations with pharmaceutical and biotechnology partners including Amgen, AstraZeneca, Boehringer-Ingelheim, Elan, Pfizer and Rigel.
Graffinitys unique fragment based discovery platform was invented in 1998, and has been in routine industrial use since 2002 in screening more than 85 drug targets.

Graffinity Media Contact for Europe:

Dr. Kristina Schmidt
CEO
Graffinity Pharmaceuticals GmbH
Tel. +49 6221 6510-112
kristina.schmidt@graffinity.com

Graffinity Media Contact for the Americas and Asia:

Mathias Woker
CBO
Graffinity Pharmaceuticals GmbH
Tel. +1 (401) 301-1086
mathias.woker@graffinity.com


'/>"/>
b3c newswire

Related biology news :

1. NIH expands Human Microbiome Project; funds sequencing centers and disease projects
2. BIO-key(R) Enters Strategic Partnership With Nlets
3. BIO-key(R) Enters Strategic Partnership With Nlets
4. The first DFG research centers to be funded for another four years
5. Tellme Enters Automotive Market
6. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers
7. Sicilian word enters British genetic language
8. NSF and EPA establish 2 centers for environmental implications of nanotechnology
9. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
10. Weight Watchers vs. fitness centers
11. AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: